Loading clinical trials...
Loading clinical trials...
A phase I/II trial to evaluate the safety and efficacy of nivolumab at the fixed dose 40 mg in patients with relapsed or refractory Hodgkins lymphoma.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
St. Petersburg State Pavlov Medical University
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07275216 · Classic Hodgkin Lymphoma
NCT06386315 · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, and more
NCT05909059 · Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, and more
First Pavlov State Medical University of St. Petersburg
Saint Petersburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions